NEW YORK (GenomeWeb) – Opko Health today said that its proposed acquisition of Bio-Reference Laboratories has passed US antitrust review.
Early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 was granted yesterday, Opko said. The deal is still subject to other closing conditions including the approval of BRL's shareholders.
The firm's inked the deal, valued at $1.47 billion, about a month ago. They expect to close the transaction in the second half of this year.